Clinical Services and Research, Australian Red Cross Lifeblood, Brisbane, Queensland, Australia.
Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Brisbane, Queensland, Australia.
Blood Transfus. 2022 Nov;20(6):465-474. doi: 10.2450/2022.0013-22. Epub 2022 May 19.
Antibodies against human neutrophil antigen (HNA)-3a are associated with severe cases of transfusion-related acute lung injury (TRALI). The HNA-3 system is located on choline transporter-like 2 (CTL-2) protein. CTL-2 is encoded by the gene SLC44A2 and a single-nucleotide polymorphism c.461G>A results in two antigens: HNA-3a and HNA-3b. Three HNA-3 genotypes/ phenotypes exist: HNA-3aa, HNA-3bb, and HNA-3ab. Two different pathways of anti-HNA-3a TRALI have been described: a two-hit neutrophil-dependent pathway and a one-hit neutrophil-independent pathway. However, it is not clear whether HNA-3ab heterozygous patients have a lower risk of anti-HNA-3a-mediated TRALI compared to HNA-3aa homozygous patients.
Healthy volunteers were genotyped for HNA-3 by real-time polymerase chain reaction, and phenotyped for HNA-3a by granulocyte immunofluorescence test (GIFT) and granulocyte agglutination test (GAT) against two donor sera containing anti-HNA-3a antibodies. The two sera were also used in in vitro models of human pulmonary microvascular endothelial cell (HLMVEC) cytotoxicity to investigate pathways of TRALI development.
For both anti-HNA-3a sera, GIFT results matched the genotype, with a lower GIFT ratio for HNA-3ab neutrophils compared to HNA-3aa neutrophils, whereas GAT results showed no difference in agglutination. HLMVEC cytotoxicity was not observed in a one-hit neutrophil-independent model but was observed in a two-hit neutrophil-dependent model. Differences in cytotoxicity were observed between the two anti-HNA-3a sera used. Consistent with reduced HNA-3a antigen density as measured by GIFT, HNA-3ab neutrophils mediated less HLMVEC cytotoxicity than HNA-3aa neutrophils.
HNA-3 genotype and HNA-3a antigen expression impacted the severity of anti-HNA-3a-mediated HLMVEC cytotoxicity in a two-hit neutrophil-dependent model of TRALI. Different HNA-3a antibodies might also impact the magnitude of HLMVEC cytotoxicity.
针对人类中性粒细胞抗原(HNA)-3a 的抗体与输血相关急性肺损伤(TRALI)的严重病例有关。HNA-3 系统位于胆碱转运蛋白样 2(CTL-2)蛋白上。CTL-2 由基因 SLC44A2 编码,单核苷酸多态性 c.461G>A 导致两种抗原:HNA-3a 和 HNA-3b。存在三种 HNA-3 基因型/表型:HNA-3aa、HNA-3bb 和 HNA-3ab。已经描述了两种抗 HNA-3a TRALI 的不同途径:依赖中性粒细胞的双打击途径和不依赖中性粒细胞的单打击途径。然而,目前尚不清楚 HNA-3ab 杂合患者与 HNA-3aa 纯合患者相比,是否具有较低的抗 HNA-3a 介导的 TRALI 风险。
通过实时聚合酶链反应对健康志愿者进行 HNA-3 基因分型,通过粒细胞免疫荧光试验(GIFT)和粒细胞凝集试验(GAT)对两种含有抗 HNA-3a 抗体的供体血清进行 HNA-3a 表型检测。还使用这两种血清在体外人肺微血管内皮细胞(HLMVEC)细胞毒性模型中研究 TRALI 发展的途径。
对于两种抗 HNA-3a 血清,GIFT 结果与基因型匹配,HNA-3ab 中性粒细胞的 GIFT 比值低于 HNA-3aa 中性粒细胞,而 GAT 结果显示凝集无差异。在不依赖中性粒细胞的单次打击模型中未观察到 HLMVEC 细胞毒性,但在依赖中性粒细胞的两次打击模型中观察到了细胞毒性。两种抗 HNA-3a 血清之间观察到细胞毒性的差异。与 GIFT 测量的 HNA-3a 抗原密度降低一致,HNA-3ab 中性粒细胞介导的 HLMVEC 细胞毒性低于 HNA-3aa 中性粒细胞。
在 TRALI 的依赖中性粒细胞的两次打击模型中,HNA-3 基因型和 HNA-3a 抗原表达影响抗 HNA-3a 介导的 HLMVEC 细胞毒性的严重程度。不同的 HNA-3a 抗体也可能影响 HLMVEC 细胞毒性的程度。